Moderna And Merck Say Their mRNA Cancer Vaccine Cut Death, Recurrence By 42%

TL;DR

Before you orderOffer from Amazon

Get health and wellness essentials delivered free with Prime

• Fast, free delivery on millions of items
• Prime Video, Amazon Music and more included
• Member-only deals all year

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

Moderna and Merck reported that adding their personalized mRNA vaccine intismeran to Keytruda reduced the relative risk of melanoma recurrence or death by 42% over two years, compared with Keytruda and placebo. The reported two-year recurrence-free survival was 82% with the combination and 70% with the comparison treatment; the companies have not yet supplied full study results in the source material.

Moderna and Merck said a Phase 3 trial found that their personalized mRNA cancer vaccine, intismeran, when given with Keytruda, reduced the relative risk of melanoma recurrence or death by 42% over two years compared with Keytruda and placebo. The companies’ announcement concerns patients whose melanoma had been surgically removed and could add evidence for treatment intended to reduce the chance of cancer returning.

The reported endpoint was recurrence-free survival (RFS), the period patients remain alive without their cancer returning. At two years, 82% of patients receiving intismeran plus Keytruda were alive without recurrence, compared with 70% of patients given Keytruda and placebo. The 42% figure describes the relative reduction in the risk of recurrence or death, not a 42-percentage-point difference in the share of patients who remained recurrence-free.

The companies also reported a 38% relative reduction in the risk of distant metastasis or death, using distant metastasis-free survival (DMFS). This measures the period patients remain alive without cancer returning at a site away from where it began. At the reported assessment, 88.5% in the combination group were alive without distant metastasis, compared with 80% in the Keytruda-placebo group.

Intismeran, also called mRNA-4157, is designed around mutations identified in an individual patient’s tumor. Researchers compare genetic sequences from cancer and healthy cells, then select cancer-specific mutations; the synthetic mRNA can encode up to 34 of them. The intended effect is to help the immune system recognize and target cancer cells. The reported trial compared the vaccine-plus-Keytruda regimen with Keytruda and placebo.

A Possible Added Option After Melanoma Surgery

The results address a key question in adjuvant melanoma treatment: whether a personalized vaccine can improve outcomes when added to an existing immunotherapy after surgery. The reported differences in RFS and DMFS suggest the combination may help more patients remain free of recurrence or distant spread during the measured period. These outcomes matter because surgery removes visible disease, but patients can still face a risk that melanoma returns.

The figures are encouraging but do not establish that the vaccine cures melanoma or benefits every patient. They describe outcomes for groups in a trial over a specific follow-up period. To judge the treatment’s place in care, clinicians and regulators will need the complete study data, including details about side effects, patient characteristics, statistical analysis and longer-term outcomes. The report also does not establish whether the approach applies to other cancers or stages of melanoma.

How the Vaccine Trial Fits Earlier Evidence

The Phase 3 announcement follows an earlier five-year Phase 2 trial of intismeran with Keytruda in melanoma. As reported by Ars Technica, that study showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death. The newly reported Phase 3 estimates are smaller: 42% for recurrence or death and 38% for distant metastasis or death. Differences between trials can reflect study design, participants, follow-up and analysis, so the percentages alone do not explain why the estimates differ.

Merck’s Keytruda, or pembrolizumab, is an established immunotherapy used in melanoma care. In the trial described in the announcement, it was given to both groups, allowing researchers to assess the addition of the personalized vaccine against a Keytruda-and-placebo comparison. Merck Research Laboratories president Dean Li described the findings as a major advance, but that characterization is the company’s interpretation, not an independent assessment of the full results.

“The trial “is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma, setting a new benchmark in the adjuvant setting and representing one of the most significant advances in melanoma treatment since the advent of immunotherapy.””

— Dean Li, president of Merck Research Laboratories

Full Trial Data Still Awaited

The source report describes the results as coming from a company announcement and notes that the release provided limited detail. Full Phase 3 results—including the number of participants, confidence intervals, statistical significance, adverse events and duration of follow-up—are not included in the material provided here. It is also unclear from that material when the complete findings will be published or presented for independent review.

The reported percentages do not show how outcomes may vary among patient groups, or how long the benefit lasts beyond the two-year assessment. The relative risk reductions should not be confused with absolute percentage-point changes: the reported RFS shares were 82% and 70%, while the companies’ 42% figure describes relative risk. Further evidence is needed to establish the treatment’s safety profile and how it might be used in practice.

Publication and Regulatory Review Ahead

The next steps will depend on the companies’ release of detailed trial findings and any submission for regulatory review. A complete report should allow researchers and clinicians to examine the study methods, statistical results, side effects and longer-term follow-up. Regulatory status and availability are not established by the announcement described in the source material, and no approval timeline is provided.

For patients and care teams, the immediate development is evidence from a Phase 3 comparison, not a change in treatment guidance on its own. Any decision about melanoma treatment should be made with a qualified oncology professional using the full evidence and a patient’s individual circumstances.

Key Questions

What did the trial report about intismeran?

Moderna and Merck reported that adding intismeran to Keytruda reduced the relative risk of melanoma recurrence or death by 42% over two years compared with Keytruda and placebo.

Does the 42% figure mean 42% fewer patients had a recurrence?

No. It is a reported relative reduction in risk, not a 42-percentage-point change. The reported two-year recurrence-free survival was 82% with the combination and 70% with Keytruda and placebo.

What is intismeran?

Intismeran, also called mRNA-4157, is a personalized mRNA vaccine designed using selected mutations from a patient’s tumor. The approach aims to prompt an immune response against cancer-specific targets.

Is the vaccine approved for melanoma treatment?

The source material reports trial results but does not establish that intismeran is approved or available as standard treatment. Regulatory status and any application timeline remain unclear.

What information is still needed?

The full Phase 3 findings are needed to assess statistical detail, side effects, participant groups and longer-term outcomes. Those details are not provided in the company announcement described in the source material.

Source: hn